Page 3 - Value Act News Today : Breaking News, Live Updates & Top Stories | Vimarsana

By Reuters Staff 2 Min Read (Reuters) - U.S. activist investor ValueAct has built a stake of 5.2% in Stroeer, the German digital and outdoor advertiser said on Wednesday, following negative publicity around stock loans taken out by the company’s top investor. Stroeer disclosed the stake, worth about $250 million as of Wednesday’s close, in a filing under German stock exchange rules requiring companies to report share holdings when they clear key thresholds - in this case a 5% barrier. ValueAct was not immediately available for comment. Shares in Stroeer shed 10% on Feb. 22 after Manager m...

Carl Icahn disclossed a 7.8% stake in Bausch Health Companies in early February. As the largest shareholder, he will leverage his position to push the company in the right direction. Icahn joins other activist investors expecting maximum value from a business seperation transaction. Legendary fund manager and activist investor Carl Icahn accumulated a 7.8% stake in Bausch Health Companies Inc (NYSE: BHC) and will likely leverage his status as the company’s largest shareholder to push for change. Icahn’s stake Icahn disclosed a 27.8 million share position in Bausch Health, formerly known a...

While he is not slowing down at all, Icahn recently reached an agreement with his son, Brett Icahn, to rejoin the firm as the eventual successor.

By Reuters Staff 2 Min Read TOKYO (Reuters) - Japanese chip and display materials maker JSR Corp said on Monday it will nominate a partner of activist investor ValueAct Capital to be an external board director, a rare move in the country where activists are still viewed with suspicion by many. The nominee, ValueAct’s Robert Hale, marked a milestone in Japan’s corporate governance two years ago by joining the board of medical equipment and camera maker Olympus Corp. ValueAct Capital became a major shareholder in JSR with more than a 7% stake early last year. JSR, established in 1957 as a g...

By Reuters Staff 2 Min Read TOKYO (Reuters) - Japanese chip and display materials maker JSR Corp said on Monday it will nominate a partner of activist investor ValueAct Capital to be an external board director, a rare move in the country where activists are still viewed with suspicion by many. The nominee, ValueAct’s Robert Hale, marked a milestone in Japan’s corporate governance two years ago by joining the board of medical equipment and camera maker Olympus Corp. ValueAct Capital became a major shareholder in JSR with more than a 7% stake early last year. JSR, established in 1957 as a g...